CDK
Gli inibitori delle chinasi ciclina-dipendenti (CDK) sono composti che bloccano l'attività delle CDK, un gruppo di chinasi proteiche che regolano il ciclo cellulare, la trascrizione e altri processi cellulari. Le CDK vengono attivate legandosi alle cicline e la loro attività è cruciale per la progressione delle cellule attraverso le diverse fasi del ciclo cellulare. Inibire le CDK può bloccare la divisione cellulare, portando all'arresto del ciclo cellulare e all'apoptosi, in particolare nelle cellule tumorali in cui le CDK sono spesso disregolate. Gli inibitori delle CDK sono ampiamente utilizzati nella ricerca sul cancro e hanno un potenziale terapeutico nel trattamento di vari tipi di cancro. Presso CymitQuimica, offriamo una selezione completa di inibitori delle CDK di alta qualità per supportare la tua ricerca sul controllo del ciclo cellulare, sul cancro e sullo sviluppo terapeutico.
Trovati 577 prodotti per "CDK".
Filtra per
Percentuale di purezza
0
100
|
0
|
50
|
90
|
95
|
100
- Prezzo più basso
- Prezzo più alto
- Purezza più bassa
- Purezza più alta
- Consegna più veloce
Abemaciclib metabolite M18
CAS:Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.Formula:C25H28F2N8OPurezza:98%Colore e forma:SolidPeso molecolare:494.54Multi-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesPurezza:98%Colore e forma:Odour SolidDN1679
DN1679 is a potent, selective, and orally active CRBN-dependent dual degrader of CDK12/13 PROTAC. It exhibits DC50 values for CDK12/13 at 8.8/9.8 nM in MDA-MB-231 cells, 5.1/6.4 nM in MDA-MB-157 cells, and 17.2/15.8 nM in MDA-MB-468 cells. DN1679 downregulates mRNA levels of DNA damage response genes such as ATM, ATR, BRCA1, and RAD51. When used in combination with Olaparib, DN1679 shows a significant synergistic anti-tumor effect. It is applicable in research on triple-negative breast cancer.YKL-5-124 TFA
CAS:YKL-5-124 TFA is a potent CDK7 inhibitor (IC50: 53.5 nM), more than 100x selective over CDK9/2, not active on CDK12/13, and disrupts the cell cycle.Formula:C30H34F3N7O5Colore e forma:SolidPeso molecolare:629.6301CDK9-IN-25
CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.Formula:C15H16FN5Purezza:98%Colore e forma:SolidPeso molecolare:285.32PROTAC FLT3/CDKs degrader-1
PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.Formula:C40H42N12O5Colore e forma:SolidPeso molecolare:770.34011CDK9 inhibitor HH1
CAS:CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.Formula:C13H15N3OSPurezza:99.92%Colore e forma:SolidPeso molecolare:261.343CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.Colore e forma:Odour SolidCDK12-IN-6
CAS:CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).Formula:C20H21F2N9Colore e forma:SolidPeso molecolare:425.448PROTAC CDK9 degrader-11
CAS:PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC CDK9 degrader with a DC50 of 1.09 nM. This compound exhibits cytotoxicity in small cell lung cancer (SCLC) cells, with IC50 values in the nanomolar range. It induces cell cycle arrest at the G0/G1 phase and inhibits cell invasion in DMS114 and DMS53 cells. In addition, PROTAC CDK9 degrader-11 shows antitumor activity in an NCI-H446 xenograft mouse model. (Pink: ligand for target protein CDK9 ligand 3; Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56)Formula:C39H48Cl2N10O5Colore e forma:SolidPeso molecolare:807.768EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Formula:C24H16N6OS2Purezza:98%Colore e forma:SolidPeso molecolare:468.55LL-K8-22
LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.Formula:C37H43N5OColore e forma:SolidPeso molecolare:573.77PP-C8
PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.Formula:C43H51FN12O7Colore e forma:SolidPeso molecolare:866.94CDK9 ligand 3
CAS:CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.Formula:C18H18BrCl2N5O3Colore e forma:SolidPeso molecolare:503.177KB-0742 hydrochloride
KB-0742 hydrochloride is a potent, selective, and orally active CDK9 inhibitor, with an IC50 of 6 nM for CDK9/cyclin T1. It exhibits over 50 times selectivity towards CDK9/cyclin T1 compared to other CDK kinases. Additionally, KB-0742 hydrochloride demonstrates effective antitumor activity.[Ala92]-p16 (84-103)
CAS:Peptide derived from the tumor suppressor protein p16; inhibits cyclin-dependent kinase-4 (cdk4)/cyclin D1 (IC50 ~ 1.5 μM) and binds to cdk6.Formula:C93H155N31O26Purezza:98%Colore e forma:SolidPeso molecolare:2123.44NecroIr2
NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.Formula:C46H30ClIrN6O2Colore e forma:SolidPeso molecolare:926.44CDK5-IN-2
CAS:CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).Formula:C29H28FN5OColore e forma:SolidPeso molecolare:481.56Roccellic Acid
CAS:Roccellic acid from R. montagnei lichen has antibacterial, anticancer properties; MIC 46.9 μg/ml; inhibits cancer cells by up to 87.9%.Formula:C17H32O4Colore e forma:SolidPeso molecolare:300.4336CDK12-IN-4
CAS:CDK12-IN-4 is a pyrazolotriazine that inhibits CDK12 (IC50: 0.641 μM) with high ATP (2 mM) and spares CDK2/Cyclin E and CDK9/Cyclin T1 (IC50: >20 μM).Formula:C20H20F2N8OColore e forma:SolidPeso molecolare:426.432
![[Ala92]-p16 (84-103)](https://static.cymitquimica.com/products/TM/thumb-webp/TP2133.webp)
